clinical trial · NCT07205159
A Study to Evaluate the Safety and Efficacy of FB102 in Patients With Severe to Very Severe Alopecia Areata.
Alopecia AreataFB102Placebo
brief summary
This is a randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of FB102 in patients with severe to very severe alopecia areata (AA).
started
Oct 23, 2025
primary completion
Mar 10, 2027
completion
Mar 10, 2027
last updated
Nov 20, 2025
detailed description
Up to approximately 32 participants who meet all the Screening eligibility criteria will be randomized in a 3:1 ratio to receive FB102, or placebo dosing to match.
official title
A Randomized, Double-Blind, Placebo-Controlled, Multi-center Study to Evaluate the Safety and Efficacy of FB102 in Patients With Severe to Very Severe Alopecia Areata.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol